JP2017119702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017119702A5 JP2017119702A5 JP2017002944A JP2017002944A JP2017119702A5 JP 2017119702 A5 JP2017119702 A5 JP 2017119702A5 JP 2017002944 A JP2017002944 A JP 2017002944A JP 2017002944 A JP2017002944 A JP 2017002944A JP 2017119702 A5 JP2017119702 A5 JP 2017119702A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- alkyl group
- hydrogen atom
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 71
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 125000005843 halogen group Chemical group 0.000 claims 29
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 12
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 12
- 208000004296 neuralgia Diseases 0.000 claims 12
- 208000021722 neuropathic pain Diseases 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 230000000069 prophylactic effect Effects 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004442 acylamino group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- -1 methylenedioxy Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 1
- 0 CC1N(C)CCN(*)C1 Chemical compound CC1N(C)CCN(*)C1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011116965 | 2011-05-25 | ||
| JP2011116965 | 2011-05-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516451A Division JP6325252B2 (ja) | 2011-05-25 | 2012-05-25 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017119702A JP2017119702A (ja) | 2017-07-06 |
| JP2017119702A5 true JP2017119702A5 (enExample) | 2018-03-01 |
Family
ID=47217366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516451A Active JP6325252B2 (ja) | 2011-05-25 | 2012-05-25 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
| JP2017002944A Pending JP2017119702A (ja) | 2011-05-25 | 2017-01-11 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516451A Active JP6325252B2 (ja) | 2011-05-25 | 2012-05-25 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20140163013A1 (enExample) |
| EP (1) | EP2716302B1 (enExample) |
| JP (2) | JP6325252B2 (enExample) |
| CA (1) | CA2840336C (enExample) |
| ES (1) | ES2653244T3 (enExample) |
| WO (1) | WO2012161301A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6247004B2 (ja) | 2010-11-05 | 2017-12-13 | 国立大学法人九州大学 | 帯状疱疹関連通の急性期疼痛の予防又は治療剤 |
| EP2803662B1 (en) * | 2012-01-13 | 2017-03-01 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| US9873683B2 (en) | 2013-07-12 | 2018-01-23 | Nippon Chemiphar Co., Ltd | P2X4 receptor antagonist |
| CA2921200C (en) | 2013-07-12 | 2021-07-13 | Nippon Chemiphar Co., Ltd. | Diazepinyl derivatives and compositions therof useful as p2x4 receptor antagonist |
| WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
| WO2019222850A1 (en) * | 2018-05-23 | 2019-11-28 | Wex Pharmaceuticals Inc. | Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain |
| JP2022163241A (ja) * | 2019-09-13 | 2022-10-26 | 日本ケミファ株式会社 | Ｐ２ｘ４受容体拮抗剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312969A1 (de) * | 2003-03-24 | 2004-10-07 | Bayer Healthcare Ag | Benzofuro-1,4-diazepin-2-on-Derivate |
| JP2009057281A (ja) * | 2005-12-19 | 2009-03-19 | Nippon Chemiphar Co Ltd | Ｐ２ｘ４受容体拮抗剤 |
| JP2009062278A (ja) * | 2005-12-29 | 2009-03-26 | Nippon Chemiphar Co Ltd | Ｐ２ｘ４受容体拮抗剤 |
| JPWO2008020651A1 (ja) * | 2006-08-17 | 2010-01-07 | 国立大学法人九州大学 | Ｐ２ｘ４受容体アンタゴニスト |
| KR20090055001A (ko) * | 2006-08-25 | 2009-06-01 | 닛뽕 케미파 가부시키가이샤 | Ｐ2ｘ4 수용체 길항제 |
| WO2008079228A1 (en) * | 2006-12-20 | 2008-07-03 | Danisco Us, Inc., Genencor Division | Assays for improved fungal strains |
| JP2012087053A (ja) * | 2009-02-03 | 2012-05-10 | Nippon Chemiphar Co Ltd | ジアゼピンジオン誘導体 |
| PL2397480T3 (pl) * | 2009-02-16 | 2014-01-31 | Nippon Chemiphar Co | Pochodna diazepinodionu |
| JP6247004B2 (ja) * | 2010-11-05 | 2017-12-13 | 国立大学法人九州大学 | 帯状疱疹関連通の急性期疼痛の予防又は治療剤 |
-
2012
- 2012-05-25 ES ES12789670.2T patent/ES2653244T3/es active Active
- 2012-05-25 EP EP12789670.2A patent/EP2716302B1/en active Active
- 2012-05-25 WO PCT/JP2012/063424 patent/WO2012161301A1/ja not_active Ceased
- 2012-05-25 JP JP2013516451A patent/JP6325252B2/ja active Active
- 2012-05-25 US US14/119,223 patent/US20140163013A1/en not_active Abandoned
- 2012-05-25 CA CA2840336A patent/CA2840336C/en active Active
-
2016
- 2016-10-28 US US15/337,384 patent/US20170065608A1/en not_active Abandoned
-
2017
- 2017-01-11 JP JP2017002944A patent/JP2017119702A/ja active Pending
-
2018
- 2018-10-17 US US16/163,108 patent/US20190046539A1/en not_active Abandoned
-
2022
- 2022-10-17 US US17/967,676 patent/US20230059381A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2495873C2 (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
| RU2475478C2 (ru) | Соединения для лечения пролиферативных расстройств | |
| JP2009515988A5 (enExample) | ||
| BRPI0618589B8 (pt) | composto de oxazol, composição farmacêutica compreendendo o referido composto, processos de fabricação e usos dos mesmos | |
| JP2010504908A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| JP2004137288A5 (enExample) | ||
| JP2015512939A5 (enExample) | ||
| JP2016501882A5 (enExample) | ||
| JP2015181191A5 (enExample) | ||
| Yu et al. | Fundamental structure–Activity relationships associated with a new structural class of respiratory syncytial virus inhibitor | |
| El-Enany et al. | Synthesis and molecular docking of some new bis-thiadiazoles as anti-hypertensive α-blocking agents | |
| EA200401608A1 (ru) | Ингибиторы ассоциированной с иммунитетом протеинкиназы | |
| JP2006522035A5 (enExample) | ||
| CY1111922T1 (el) | 1-ετεροκυκλυλσουλφονυλ, 2-αμινομεθυλ, 5-(ετερο-)αρυλ υποκατεστημενα 1-η-πυρρολιου παραγωγα ως αναστολεις εκκρισης οξεος | |
| AR111466A1 (es) | Inhibidores de hdac6 selectivos | |
| NO20075086L (no) | Behandling av Parkinsons sykdom, obstruktiv sovn apne, demens med Lewy legemer, vaskulaer demens med ikke-imidazol alkylamin histamin H3-reseptor ligander | |
| AR053548A1 (es) | Derivados de oxiindol | |
| RU2005133994A (ru) | Оксимные производные и их применение в качестве фармацевтически активных агентов | |
| JP2020507566A5 (enExample) | ||
| RU2015131139A (ru) | Галогензамещенное гетероциклическое соединение | |
| JP2017506248A5 (enExample) | ||
| JP2015522607A5 (enExample) | ||
| Mathew et al. | Synthesis, preclinical evaluation and antidepressant activity of 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1H-pyrazole-1-carbothioamides | |
| JO3610B1 (ar) | مشتقات كربوكساميد |